Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Bleomycin is a chemotherapy agent with known pulmonary toxicity.
• Corticosteroids are the primary treatment for bleomycin-induced pulmonary toxicity.
• Corticosteroid unresponsiveness occurs in a subset of patients, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To report a case of bleomycin-induced pulmonary toxicity unresponsive to corticosteroids.
• To evaluate the efficacy of adding imatinib to corticosteroid treatment in such cases.

Main Methods:

• A 51-year-old male seminoma patient developed pulmonary toxicity during bleomycin, etoposide, and cisplatin chemotherapy.
• Initial treatment with methylprednisolone was ineffective, leading to respiratory failure.
• Imatinib was added to methylprednisolone, and treatment outcomes were monitored.

Main Results:

• Computed thorax tomography revealed bilateral lung consolidation.
• Bronchoalveolar lavage showed neutrophilia, and biopsy indicated fibroblastic proliferation.
• Combination therapy with corticosteroids and imatinib resulted in successful treatment, allowing discontinuation of both agents.

Conclusions:

• Imatinib may serve as a viable alternative treatment option for bleomycin-induced pulmonary toxicity refractory to corticosteroid therapy.
• This case highlights the potential of targeted therapy in managing severe chemotherapy-induced lung injury.
• Further research is warranted to explore the role of imatinib in bleomycin pulmonary toxicity.